Clinical Evaluation of the Efficacy of a Nasal Spray in the Treatment of Nasal Dryness

NCT07657247 | Not Yet Recruiting

• 1 other identifier: STUU526AA0790
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to see whether the nasal spray can help improve hydration of the nasal mucosa, reduce discomfort linked to nasal dryness, and confirm its safety in patients suffering from nasal dryness.

Conditions

Nasal Dryness

Outcome Measures

Primary Outcomes (1)

• Improvement of the nasal dryness symptoms

  The changes between the baseline and day 7 will be assessed using the Rhinitis Sicca Symptom Score (RSSS). The RSSS is constituted by the sum of the following individual symptoms: sensation of dry nose, impairment of nasal breathing/nasal obstruction, crusting, itching/sneezing attacks, pain in the nose, anterior nasal discharge /runny nose, thick nasal discharge, desire to clear one's throat/ dry throat, impairment of smell and impairment of sleep. Patients assessed with each of these symptoms on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).

  Day 0 - Day 0 immediately after first use - Day 7

Secondary Outcomes (2)

• Improvement of the total perceive Nasal symptom relief

  Day 0 - Day 0 immediately after first use - Day 7

• Incidence of Adverse Events

  through study completion, an average of 7 days

Study Arms (1)

Nasal spray

EXPERIMENTAL

Device: Spray pompe nasal

Interventions

Spray pompe nasal DEVICE

Dosage: 2 sprays per nostril

Nasal spray

Eligibility Criteria

• Age: 6 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Gender: female and/or male.
• Age: adults and children from 6 years old:
• The physician's score for at least two symptoms, in addition to a dry nose, must average at least 2 at the enrolment visit (Day 0), for a minimum total score of 6.
• Subjects agree to refrain from taking any medication and/or taking any action to relieve nasal symptoms throughout the study, from Day -4 to Day 7, apart from acetaminophen.
• Autonomous adult, or minor with the consent of their legal representative.
• Subject and/or Parent/legal guardian of the subject has given freely and expressly her/his informed consent.
• Subject and/or Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected.
• Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use.
• Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor.

You may not qualify if:

• Subjects taking anticoagulants, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), or topical or systemic decongestants within two weeks prior to Visit 1 and during the study.
• Subjects using other nasal sprays, nasal pumps, nasal irrigation/rinsing devices, or oils, creams, or gels in the nose within two weeks prior to Visit 1 and during the study.
• Subjects with a history of sensitivity to products related to the product being evaluated.
• Subjects with any clinically significant comorbid condition that, in the opinion of the principal investigator, could affect the subject's safety and/or participation in the study.
• Person whose ability to use the product daily and complete the daily follow-up diary is in doubt.
• Person refusing to sign the informed consent form prior to the study.
• Person participating or having participated in any other clinical study within the 30 days preceding the study.
• Person participating in any other clinical study.

Sponsors & Collaborators

• YSLab: lead
• Eurofins: collaborator

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2026
• First Posted: June 18, 2026
• Study Start (Estimated): December 15, 2026
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: June 18, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share